The patent protects InSpan’s unique approach to spinal fixation that allows for less invasive surgery with quicker recovery times and less blood loss in the ASC setting.
In 2021, InSpan became the first interspinous-interlaminar plate fixation device granted the dual FDA approval for spinal fusion and spinal stenosis from T1-S1 in selected patients, according to a March 21 press release.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
